Fluvoxamine is a prescription antidepressant that belongs to the selective serotonin reuptake inhibitor (SSRI) class. Its active component is Fluvoxamine Maleate, which is supplied as an oral pill in strengths of 50 mg and 100 mg. In Hong Kong, the medication is regulated by the Department of Health and can only be obtained with a physician’s prescription. It is primarily indicated for obsessive-compulsive disorder (OCD) and several anxiety-related conditions, while also being prescribed for major depressive episodes in certain clinical contexts.
Fluvoxamine selectively blocks the serotonin transporter (SERT) on presynaptic neurons. By inhibiting reuptake, it increases the concentration of serotonin in the synaptic cleft, enhancing serotonergic neurotransmission. This elevation helps to normalize mood and anxiety pathways that are often dysregulated in OCD and related disorders.
These indications are recognized by the Hong Kong Department of Health and align with international regulatory approvals.
Fluvoxamine has been investigated for several off-label applications. While not approved by regulatory agencies for these purposes, clinical research provides modest support:
Disclaimer: Off-label use of Fluvoxamine requires supervision by a qualified healthcare provider and a personalized risk-benefit assessment.
Patients with a history of bipolar disorder should be evaluated for manic switch risk before initiating therapy.
If patients are taking over-the-counter supplements or herbal products (e.g., St John’s wort), they should inform their prescriber to assess interaction risk.
This article provides educational information about Fluvoxamine and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Combining Fluvoxamine with another SSRI or tricyclic antidepressant increases the risk of serotonin syndrome. If a switch between antidepressants is needed, a washout period of at least 2 weeks (or longer, depending on the agents) is generally recommended.
Fluvoxamine is not known to cause major changes in blood pressure. However, rare cases of orthostatic hypotension have been reported, especially in the elderly. Monitoring is advisable when initiating therapy in patients with existing hemodynamic instability.
Take the missed dose as soon as you remember, unless it is within 6 hours of the next scheduled dose. In that case, skip the missed tablet and continue with your regular dosing schedule to avoid double-dosing.
In Hong Kong, the 50 mg tablets are typically round and white, while the 100 mg tablets are often oval and marked with a “100” imprint. Always verify the imprint code on the packaging before ingestion.
Weight gain or loss is not a prominent side effect of Fluvoxamine. Some patients report mild appetite suppression early in treatment, which usually normalises after several weeks.
Fluvoxamine passes into breast milk in small amounts. While many clinicians consider it relatively safe, a risk-benefit discussion with a healthcare provider is essential before use during lactation.
Fluvoxamine inhibits CYP1A2, an enzyme that metabolises caffeine. Consequently, caffeine clearance may be reduced, leading to increased stimulant effects. Moderation of caffeine intake is advisable.
Symptoms include hives, swelling of the face or throat, difficulty breathing, and a rapid heartbeat. Seek emergency medical attention immediately if these occur.
Most antihistamines do not have significant interactions with Fluvoxamine. However, sedating antihistamines (e.g., diphenhydramine) may enhance drowsiness, so patients should be cautioned about combined central nervous system depression.
Fluvoxamine is not a prohibited substance in standard workplace or athletic drug-testing programs. Nonetheless, disclose all prescription medications to the testing authority to avoid inadvertent positive results for related metabolites.
